Navigating the UK and Global Construction Landscape within the Pharma and Life-Science Sector in 2026

UK–US Pharmaceutical Deal: A Gradual Catalyst for Life-Sciences Growth

The UK’s new zero-tariff agreement with the United States marks a strategic shift in pharmaceutical trade - removing tariffs on medicines, ingredients, and med-tech exports for the first time. While the deal strengthens the UK’s position as a life-sciences hub, its impact on construction will unfold gradually.

From 2026 onwards, we expect a steady increase in demand for new and upgraded R&D, manufacturing, and GMP-compliant facilities as investment confidence builds. For those in the construction and project-management sector, this signals a period of measured but sustained growth - with opportunities emerging in high-specification, compliance-driven environments. Wade Construction Management Consultants continues to track these developments closely, supporting clients to prepare for the next phase of life-sciences expansion.

Global Outlook: Emerging Hotspots and Shifting Investment 

Internationally, the pharmaceutical construction landscape is entering a period of selective but strategic expansion.

In the United States, growth is concentrated along the East Coast corridor, from Massachusetts through Pennsylvania,  where investment in biologics and cell-and-gene therapy manufacturing remains strong, supported by major incentives under the Inflation Reduction Act.

India continues to expand rapidly as a global API and biosimilar production base, driving demand for new GMP facilities and R&D hubs around Hyderabad and Ahmedabad. Across the Asia-Pacific, Singapore and South Korea are leading in high-tech biologics and vaccine manufacturing, while emerging markets such as Vietnam and Malaysia are attracting secondary production and packaging investment.

In Europe, activity is increasingly clustered in Ireland, Belgium, and the Netherlands, where regulatory stability and skilled labour are drawing post-Brexit relocations.

Overall, the direction of travel is clear: advanced manufacturing capacity is growing in established innovation zones, while lower-cost regions are absorbing support and supply-chain infrastructure - setting the stage for a more distributed, resilient global pharma network.

Implications for our US Clients

For clients in the United States, the near-term challenge is less about opportunity and more about capacity. The surge in data centre construction, driven by AI infrastructure, cloud storage, and semiconductor projects, is creating intense competition for specialist resource, from MEP engineers to commissioning managers and clean-environment contractors. This talent draw is already pushing labour and subcontractor costs upward, particularly along the East Coast and Midwest corridors, where pharmaceutical and data sectors overlap.

As a result, pharma developers may face longer procurement cycles, reduced availability of niche trades, and upward pressure on project delivery timelines. The risk is that life-sciences expansion slows in the short term as construction capacity is absorbed elsewhere. Clients who act early, securing integrated project teams, investing in workforce retention, and locking in supply chains, will be best placed to avoid disruption and maintain momentum as the market rebalances in 2026–2027.

How Wade Can Help

At Wade Construction Management Consultants, we help clients navigate complex, high-specification environments where compliance, safety, and delivery precision are critical. Our team combines deep experience in GMP and pharmaceutical settings with proven capability across advanced manufacturing and controlled-environment projects. As markets adjust and capacity tightens, we provide the independent oversight, supply-chain stability, and strategic planning needed to keep projects moving. In a shifting global landscape, Wade ensures your facilities are built to perform, safely and sustainably.

CDM 2015 – Clarifying Roles and Responsibilities 

There remains ongoing confusion around the legal duties of the Principal Designer (PD) and Principal Contractor (PC) under CDM 2015 - particularly over what constitutes “construction work”. Failure to appoint or coordinate these roles correctly can leave clients exposed to HSE enforcement and legal risk.

HSE Priorities for 2025-2026 

The HSE will continue targeting key areas including:

• Mental health and Stress Management - integrate wellbeing into project planning.

• Asbestos Control - maintain current surveys and competent contractors. 

• Dust and Lung Disease Prevention - control exposure and monitor air quality.

• Manual Handling and Ergonomics - apply HSE’s MAC and ART tools.

• Occupational Hygiene Inspections - expect checks on COSHH, noise, and LEV.

• Building Safety Act Compliance - clearly define duty holder roles under CDM 2015 and maintain up-to-date safety case documentation 

Building Safety Act - What It Means for You

The Building Safety Regulator, now operating within HSE, continues to strengthen oversight of higher-risk buildings. Clients must ensure clear accountability structures, competence frameworks, and robust information management across all stages of design and construction. Wade CMC can help you interpret these duties and embed compliance from the outset.

Skills, Shortages, and Strategic Readiness

The UK construction industry faces one of its most sustained skills shortages in decades, with 48,000 new workers needed annually through to 2029. The pharmaceutical and life sciences sector, with its stringent regulatory and technical demands, feels this impact acutely.

Disciplines most affected will include: HVAC and critical utilities, cleanroom envelope installation, process piping, and validation-ready electrical systems.

To mitigate these risks, proactive workforce planning and supply-chain alignment are essential. Upskilling, modular construction, and digital project tools can offset labour constraints and ensure delivery continuity.

Wade CMC provides end-to-end project and construction management to keep pharma projects on time, compliant, and fully resourced. Our teams build realistic schedules and budgets, rigorously pre-qualify vendors, and anticipate constraints early to avoid impact on the critical path. Through strong competence assurance and contractor integration, Wade CMC enables clients to deliver world-class, compliant facilities in an increasingly competitive environment.

How Wade CMC Delivers Confidence in 2026 and Beyond

As the construction landscape grows more complex with rising costs, evolving regulation, sustainability targets, and an increasingly competitive skills market, success in 2026 will belong to those who plan smarter and collaborate better. Wade CMC stands at the centre of this transformation, providing integrated project and construction management that brings structure, certainty, and control to even the most challenging pharmaceutical and life sciences developments.

Our approach blends technical expertise with proactive leadership. From navigating regulatory frameworks and managing specialist trades, to embedding sustainability and digital innovation into every stage of delivery, we ensure that projects remain compliant, efficient, and future-ready. We don’t just manage suppliers, we build partnerships that drive performance, resilience, and shared accountability across the entire project lifecycle.

Whether you’re planning a new facility, upgrading an existing site, or facing delivery challenges, Wade CMC provides the clarity, capability, and commitment to make your next project a success.

For more information on how Wade CMC can help support your construction project please get in touch.